Hutchmed Share News (HCM)
HCM Share
HCM Share
HCM Share
HCM Share
HCM
HCM Share
HCM Level 2
HCM Live
HCM Broker
HCM Directors
HCM Financial
HCM
HCM Short
HCM
Last checked at -
Thu, 28th Oct 2021 21:59
Hutchmed (China) Ltd - Hong-Kong based pharmaceutical company - Begins phase 3 trial of HMPL-523 in patients suffering from immune thrombocytopenia, an autoimmune disease which increases risk of bleeding. "The first patient received their first dose on October 27, 2021," Hutchmed says.
Current stock price: 437.00 pence
Year-to-date change: down 5.0%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hutchison China Gets US FDA Fast Track Status For Surufatinib
Read moreHutchison China Sees Loss Widen But Lays "Foundations" In 2019
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read more
By Tamara Mathias, Roxanne Liu and Manojna MaddipatlaFeb 12 (Reuters) - The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of ...
Read more
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi' (durvalumab) combination in a cohort of patients with metastatic papillary renal cell carcinoma (PRCC) on Monday.
Read moreHutchison China Prices USD110 Million American Depositary Share Offer
Read moreHutchison China Plans USD110 Million American Depositary Share Offer
Read more(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.
Read moreHutchinson China Reports Early Success Of Surufatinib Phase III Study
Read moreHutchison China Starts Phase II Study For Cancer Treatment In China
Read more(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.
Read moreHutchison China Hails "Positive Step" For Cancer Treatment In China
Read moreHutchison China MediTech's Cancer Treatment Joins Key China State List
Read moreHutchison China MediTech Gets Orphan Designation For Surufatinib
Read moreCORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review
Read more
Last checked at